×
S&P 500   3,776.69 (-0.23%)
DOW   30,735.08 (-0.13%)
QQQ   277.82 (-0.88%)
AAPL   136.51 (-0.15%)
MSFT   255.95 (-0.34%)
META   156.74 (-2.80%)
GOOGL   2,137.20 (-1.93%)
AMZN   107.66 (+1.37%)
TSLA   667.38 (-0.90%)
NVDA   144.55 (-4.64%)
NIO   21.14 (-2.67%)
BABA   114.72 (+0.91%)
AMD   73.07 (-4.45%)
MU   52.33 (-5.34%)
CGC   2.85 (+0.35%)
T   21.03 (+0.33%)
GE   62.88 (-1.24%)
F   11.12 (-0.09%)
DIS   94.61 (+0.22%)
AMC   13.31 (-1.77%)
PFE   51.45 (-1.87%)
PYPL   70.14 (+0.43%)
NFLX   175.92 (+0.60%)
S&P 500   3,776.69 (-0.23%)
DOW   30,735.08 (-0.13%)
QQQ   277.82 (-0.88%)
AAPL   136.51 (-0.15%)
MSFT   255.95 (-0.34%)
META   156.74 (-2.80%)
GOOGL   2,137.20 (-1.93%)
AMZN   107.66 (+1.37%)
TSLA   667.38 (-0.90%)
NVDA   144.55 (-4.64%)
NIO   21.14 (-2.67%)
BABA   114.72 (+0.91%)
AMD   73.07 (-4.45%)
MU   52.33 (-5.34%)
CGC   2.85 (+0.35%)
T   21.03 (+0.33%)
GE   62.88 (-1.24%)
F   11.12 (-0.09%)
DIS   94.61 (+0.22%)
AMC   13.31 (-1.77%)
PFE   51.45 (-1.87%)
PYPL   70.14 (+0.43%)
NFLX   175.92 (+0.60%)
S&P 500   3,776.69 (-0.23%)
DOW   30,735.08 (-0.13%)
QQQ   277.82 (-0.88%)
AAPL   136.51 (-0.15%)
MSFT   255.95 (-0.34%)
META   156.74 (-2.80%)
GOOGL   2,137.20 (-1.93%)
AMZN   107.66 (+1.37%)
TSLA   667.38 (-0.90%)
NVDA   144.55 (-4.64%)
NIO   21.14 (-2.67%)
BABA   114.72 (+0.91%)
AMD   73.07 (-4.45%)
MU   52.33 (-5.34%)
CGC   2.85 (+0.35%)
T   21.03 (+0.33%)
GE   62.88 (-1.24%)
F   11.12 (-0.09%)
DIS   94.61 (+0.22%)
AMC   13.31 (-1.77%)
PFE   51.45 (-1.87%)
PYPL   70.14 (+0.43%)
NFLX   175.92 (+0.60%)
S&P 500   3,776.69 (-0.23%)
DOW   30,735.08 (-0.13%)
QQQ   277.82 (-0.88%)
AAPL   136.51 (-0.15%)
MSFT   255.95 (-0.34%)
META   156.74 (-2.80%)
GOOGL   2,137.20 (-1.93%)
AMZN   107.66 (+1.37%)
TSLA   667.38 (-0.90%)
NVDA   144.55 (-4.64%)
NIO   21.14 (-2.67%)
BABA   114.72 (+0.91%)
AMD   73.07 (-4.45%)
MU   52.33 (-5.34%)
CGC   2.85 (+0.35%)
T   21.03 (+0.33%)
GE   62.88 (-1.24%)
F   11.12 (-0.09%)
DIS   94.61 (+0.22%)
AMC   13.31 (-1.77%)
PFE   51.45 (-1.87%)
PYPL   70.14 (+0.43%)
NFLX   175.92 (+0.60%)
NASDAQ:CRDF

Cardiff Oncology Stock Forecast, Price & News

$2.19
-0.01 (-0.45%)
(As of 07/1/2022 01:04 PM ET)
Add
Compare
Today's Range
$2.18
$2.44
50-Day Range
$1.17
$2.29
52-Week Range
$1.13
$8.58
Volume
15,146 shs
Average Volume
909,785 shs
Market Capitalization
$94.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75
30 days | 90 days | 365 days | Advanced Chart

Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

CRDF Stock Forecast (MarketRank)

Overall MarketRank

1.87 out of 5 stars

Medical Sector

720th out of 1,429 stocks

Biological Products, Except Diagnostic Industry

116th out of 217 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
Cardiff Oncology logo

About Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF Stock News Headlines

Cardiff Oncology: Risky Investment
HC Wainwright lowers Cardiff Oncology PT to $22
Cardiff Oncology: Q4 Earnings Insights
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
22
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/01/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+527.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-28.29 million
Net Margins
-9,447.37%
Pretax Margin
-9,447.37%

Debt

Sales & Book Value

Annual Sales
$360 thousand
Book Value
$3.55 per share

Miscellaneous

Free Float
41,790,000
Market Cap
$94.84 million
Optionable
Not Optionable
Beta
2.04














Cardiff Oncology Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardiff Oncology stock.
View analyst ratings for Cardiff Oncology
or view top-rated stocks.

What is Cardiff Oncology's stock price forecast for 2022?

4 Wall Street analysts have issued 1 year price objectives for Cardiff Oncology's shares. Their CRDF stock forecasts range from $7.00 to $22.00. On average, they expect Cardiff Oncology's stock price to reach $13.00 in the next year. This suggests a possible upside of 493.6% from the stock's current price.
View analysts' price targets for Cardiff Oncology
or view top-rated stocks among Wall Street analysts.

How has Cardiff Oncology's stock performed in 2022?

Cardiff Oncology's stock was trading at $6.01 on January 1st, 2022. Since then, CRDF stock has decreased by 63.6% and is now trading at $2.19.
View the best growth stocks for 2022 here
.

When is Cardiff Oncology's next earnings date?

Cardiff Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Cardiff Oncology
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its earnings results on Thursday, May, 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 25.12% and a negative net margin of 9,447.37%.
View Cardiff Oncology's earnings history
.

Who are Cardiff Oncology's key executives?

Cardiff Oncology's management team includes the following people:
  • Dr. Mark Erlander Ph.D., CEO & Director (Age 62, Pay $783.23k)
  • Mr. James E. Levine, Chief Financial Officer (Age 51, Pay $585.16k) (LinkedIn Profile)
  • Ms. Vicki Kelemen, Chief Operating Officer (LinkedIn Profile)
  • Dr. Tod Smeal Ph.D., Chief Scientific Officer?
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. Charles Monahan R.Ph., Sr. VP of Regulatory Affairs

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

How do I buy shares of Cardiff Oncology?

Shares of CRDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiff Oncology's stock price today?

One share of CRDF stock can currently be purchased for approximately $2.19.

How much money does Cardiff Oncology make?

Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $94.84 million and generates $360 thousand in revenue each year. The company earns $-28.29 million in net income (profit) each year or ($0.820010) on an earnings per share basis.

How many employees does Cardiff Oncology have?

Cardiff Oncology employs 22 workers across the globe.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for Cardiff Oncology is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at [email protected].

This page (NASDAQ:CRDF) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.